GERN — Geron Corporation

Geron Corporation Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $57.5 million for Q2 2026, representing a 17% increase year-over-year and an 11% increase quarter-over-quarter. Year-to-date, net revenue grew approximately 24% compared to the same period in 2025.
• Gross to Net Deductions: Increased to 20.7% in Q2 2026 from 15.3% in Q2 2025; expected to remain in the low to mid-20s for the remainder of the year.
• Operating Expenses: Total operating expenses decreased by 4% year-over-year in the first half of 2026, totaling $60.7 million for Q2 2026.
• Cash Position: $327 million in cash and equivalents as of June 30, 2026, down from $341 million at the end of Q1 2026.

2. Strategic Updates and Business Highlights

• RYTELO Commercialization: Continued expansion in the U.S. market with a focus on second-line treatment for lower-risk MDS patients. Achieved 5% demand growth and an 8% increase in prescribing accounts in Q2.
• Clinical Evidence: Presented real-world evidence at EHA supporting RYTELO's efficacy in lower-risk MDS, consistent with Phase III IMerge trial results.
• Leadership Changes: Appointment of Chinmaya Rath as Chief Business Officer to enhance business development and strategic growth initiatives.
• European Market Exploration: Plans to share European commercialization strategies by year-end, with a focus on navigating pricing dynamics and potential partnerships.

3. Forward Guidance and Outlook

• Revenue Guidance: Anticipating full-year 2026 RYTELO net product revenue in the mid- to high end of the $220 million to $240 million range.
• Operating Expenses: Expected to be in the range of $230 million to $240 million for 2026, reflecting continued investment in commercialization efforts while maintaining financial discipline.

4. Bad News, Challenges, or Points of Concern

• Gross to Net Deductions: The increase in deductions could impact net revenue realization.
• Regulatory Engagement: Ongoing discussions with the FDA regarding interim analysis thresholds for the Phase III IMpactMF trial, with no changes to the final overall survival analysis timeline.
• Market Competition: The evolving landscape in Europe and the U.S. may pose challenges in pricing and market access, especially with the MFN (Most Favored Nation) dynamics.

5. Notable Q&A Insights

• Seasonality Impact: Management is confident in maintaining consistent revenue growth despite potential seasonal fluctuations, with inventory management strategies in place.
• Growth Sources: Revenue growth is attributed to both new and existing accounts, with a notable increase in community treatment centers.
• Persistence on Therapy: There are challenges in tracking therapy duration metrics, which complicates understanding patient persistence trends.
• European Strategy: Management is actively monitoring pricing dynamics and engaging with stakeholders to optimize RYTELO's launch strategy in Europe, with potential partnership discussions on the table.

Overall, Geron Corporation is demonstrating solid financial growth and strategic execution, particularly with RYTELO, while navigating challenges related to market dynamics and regulatory processes.